CN103561742B - 包含作为活性剂的苯基氨基嘧啶衍生物的制剂 - Google Patents

包含作为活性剂的苯基氨基嘧啶衍生物的制剂 Download PDF

Info

Publication number
CN103561742B
CN103561742B CN201180069095.7A CN201180069095A CN103561742B CN 103561742 B CN103561742 B CN 103561742B CN 201180069095 A CN201180069095 A CN 201180069095A CN 103561742 B CN103561742 B CN 103561742B
Authority
CN
China
Prior art keywords
pharmaceutical compositions
amount
gross weight
compositions according
relative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180069095.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103561742A (zh
Inventor
杜尔加·马赫斯瓦利·帕尔瓦塔埃尼
西达尔塔·耶德鲁里
文卡塔·萨蒂亚纳拉亚纳·阿帕德维杜拉
卡里·萨亚姆·博胡扬加·拉奥·阿迪布哈特拉
文凯阿赫·抽达利·纳纳帕那尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natco Pharma Ltd
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43923331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103561742(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of CN103561742A publication Critical patent/CN103561742A/zh
Application granted granted Critical
Publication of CN103561742B publication Critical patent/CN103561742B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN201180069095.7A 2011-03-07 2011-08-10 包含作为活性剂的苯基氨基嘧啶衍生物的制剂 Expired - Fee Related CN103561742B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1103860.1 2011-03-07
GB1103860.1A GB2488788B (en) 2011-03-07 2011-03-07 Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
PCT/IB2011/001842 WO2012120328A1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent

Publications (2)

Publication Number Publication Date
CN103561742A CN103561742A (zh) 2014-02-05
CN103561742B true CN103561742B (zh) 2016-04-27

Family

ID=43923331

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180069095.7A Expired - Fee Related CN103561742B (zh) 2011-03-07 2011-08-10 包含作为活性剂的苯基氨基嘧啶衍生物的制剂

Country Status (33)

Country Link
US (1) US9895367B2 (enExample)
EP (1) EP2683381B1 (enExample)
JP (1) JP5788534B2 (enExample)
KR (1) KR101767296B1 (enExample)
CN (1) CN103561742B (enExample)
AP (1) AP4076A (enExample)
AU (1) AU2011361921B2 (enExample)
BR (1) BR112013022930A2 (enExample)
CA (1) CA2829015C (enExample)
CO (1) CO6811851A2 (enExample)
CY (1) CY1116968T1 (enExample)
DK (1) DK2683381T3 (enExample)
EA (1) EA024610B1 (enExample)
ES (1) ES2554927T3 (enExample)
GB (1) GB2488788B (enExample)
GE (1) GEP20156410B (enExample)
HR (1) HRP20151382T1 (enExample)
HU (1) HUE025562T2 (enExample)
IL (1) IL228218A (enExample)
MA (1) MA35088B1 (enExample)
MX (1) MX339130B (enExample)
MY (1) MY158693A (enExample)
NZ (1) NZ614903A (enExample)
PH (1) PH12013501844A1 (enExample)
PL (1) PL2683381T3 (enExample)
PT (1) PT2683381E (enExample)
RS (1) RS54420B1 (enExample)
SG (1) SG193349A1 (enExample)
SI (1) SI2683381T1 (enExample)
SM (1) SMT201500235B (enExample)
UA (1) UA111074C2 (enExample)
WO (1) WO2012120328A1 (enExample)
ZA (1) ZA201306643B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1254573A1 (zh) * 2015-12-18 2019-07-19 Natco Pharma Limited 包含苯基氨基嘧啶衍生物的药物组合物
WO2017115316A1 (en) * 2015-12-29 2017-07-06 Noivita S.R.L.S. Lipophilic formulations
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
CN107564610A (zh) * 2017-10-20 2018-01-09 浙江中大元通特种电缆有限公司 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆
SG11202008226YA (en) 2018-03-14 2020-09-29 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
CN113473974A (zh) * 2019-01-25 2021-10-01 深圳市药欣生物科技有限公司 药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1261790A (zh) * 1997-07-29 2000-08-02 法玛西雅厄普约翰美国公司 亲脂性化合物的自体乳化剂
US20080274173A1 (en) * 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents
US20080306100A1 (en) * 2004-09-09 2008-12-11 Natco Pharma Limited Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
EP1498143A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
EP2076507A2 (en) * 2006-10-26 2009-07-08 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
MY175373A (en) 2008-03-04 2020-06-23 Natco Pharma Ltd Crystal form of phenylamino pyrimidine derivatives
US8067422B2 (en) * 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2010068311A1 (en) * 2008-05-23 2010-06-17 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1261790A (zh) * 1997-07-29 2000-08-02 法玛西雅厄普约翰美国公司 亲脂性化合物的自体乳化剂
US20080306100A1 (en) * 2004-09-09 2008-12-11 Natco Pharma Limited Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
US20080274173A1 (en) * 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs;R Neslihan Gursoy等;《Biomedicine & Pharmacotherapy》;20040430;第58卷(第3期);摘要，第174页表1、第174页右栏2.1.1油 *

Also Published As

Publication number Publication date
AU2011361921A2 (en) 2014-10-30
RS54420B1 (sr) 2016-04-28
ES2554927T3 (es) 2015-12-28
NZ614903A (en) 2014-08-29
CN103561742A (zh) 2014-02-05
KR20140016926A (ko) 2014-02-10
PH12013501844A1 (en) 2015-10-23
DK2683381T3 (en) 2015-12-21
HRP20151382T1 (hr) 2016-02-12
WO2012120328A1 (en) 2012-09-13
AU2011361921B2 (en) 2016-06-09
AP2013007128A0 (en) 2013-09-30
MX339130B (es) 2016-05-13
HUE025562T2 (en) 2016-03-29
UA111074C2 (uk) 2016-03-25
EA201391280A1 (ru) 2014-02-28
GEP20156410B (en) 2015-12-10
SG193349A1 (en) 2013-10-30
EP2683381B1 (en) 2015-09-16
MX2013010160A (es) 2013-12-06
GB201103860D0 (en) 2011-04-20
EP2683381A1 (en) 2014-01-15
US20130338180A1 (en) 2013-12-19
AP4076A (en) 2017-03-23
SMT201500235B (it) 2015-10-30
JP5788534B2 (ja) 2015-09-30
CO6811851A2 (es) 2013-12-16
AU2011361921A1 (en) 2013-09-26
PT2683381E (pt) 2015-11-02
SI2683381T1 (sl) 2016-01-29
CA2829015A1 (en) 2012-09-13
CA2829015C (en) 2018-01-02
GB2488788B (en) 2013-07-10
ZA201306643B (en) 2014-11-26
KR101767296B1 (ko) 2017-08-10
IL228218A (en) 2016-06-30
EA024610B1 (ru) 2016-10-31
MY158693A (en) 2016-11-15
PL2683381T3 (pl) 2016-06-30
MA35088B1 (fr) 2014-05-02
CY1116968T1 (el) 2017-04-05
BR112013022930A2 (pt) 2016-12-06
GB2488788A (en) 2012-09-12
JP2014507463A (ja) 2014-03-27
US9895367B2 (en) 2018-02-20

Similar Documents

Publication Publication Date Title
JP7071420B2 (ja) 親油性の化合物の固体経口剤形
CN103561742B (zh) 包含作为活性剂的苯基氨基嘧啶衍生物的制剂
TWI694823B (zh) 含有脂質化合物、三酸甘油酯及界面活性劑之組成物與使用該組成物之方法
WO2014009434A1 (en) Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
JP2012525409A5 (enExample)
JP2008516890A (ja) 新規なフェノフィブラート製剤および関連治療方法
WO2015186039A1 (en) Oral pharmaceutical composition of isotretinoin
JP2005537280A (ja) 不溶性薬物の可溶化用粘膜吸着性組成物及び製剤とその製造方法
JP2008534586A (ja) フェノフィブレートの改良された製剤
JP2016528218A (ja) 低水溶性薬剤の低融解イオン性塩の組成物および調製方法
KR101928589B1 (ko) 알리스포리비르를 포함하는 제약 조성물
JP2022531685A (ja) メチルナルトレキソンの液体経口投与製剤
JP2008505934A (ja) メンソール又はｐｅｇ／ポロキサマーを含むフェノフィブレートの改良された製剤
WO2025087032A1 (zh) 一种非诺贝特油性制剂、口服药物和制备方法
CN107184587B (zh) 一种2-甲氧基雌二醇口服药物组合物及其制备方法、2-甲氧基雌二醇软胶囊
KR101200169B1 (ko) 플루비프로펜을 함유하는 고체 자가 유화 약물 전달 조성물
JP2010513351A (ja) 酸を含むゼラチンカプセル剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160427

Termination date: 20200810